Skip to main content

beruzatatug pelitecan

Generic: Beruzatatug Pelitecan

beruzatatug pelitecan: 2 clinical trials tracked.

beruzatatug pelitecan evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about beruzatatug pelitecan, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Advanced Solid Tumor
Clinical Trial Registry Records (2)

A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520Registry updated 2026-08-05·Phase 1/Phase 2·BNTX
Recruiting

Primary endpoint: Part 1 - Occurrence of dose limiting toxicities (DLTs) within a participant

InterventionalRandomizedopen880 targetStarted 2025-09Completion 2030-0650 sites · Australia, China, Germany, Italy…BioNTech SE

A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors

NCT07070232Registry updated 2026-10-09·Phase 1/Phase 2·BNTX
Recruiting

Primary endpoint: Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of treatment emergent adverse events (TEAEs), treatment related adverse events (TRAEs), treatment emergent serious adverse events (TESAEs), and treatment related serious adverse events (TRSAEs)

InterventionalRandomizedopen1,438 targetStarted 2025-08Completion 2030-0377 sites · Australia, Belgium, China, Germany…BioNTech SE